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ABSTRACT
There are many misconceptions about the prevalence and 
effects of hypoglycemia in people with type 2 diabetes 
(T2D), including hypoglycemia does not occur or does 
not have adverse consequences in T2D. This narrative 
review aims to help dispel these myths. Around 25% of 
people with T2D taking insulin for >5 years were found to 
have severe hypoglycemic events, which is comparable 
to the severe hypoglycemia rate in adults with type 1 
diabetes (T1D) diagnosed within 5 years. The total number 
of hypoglycemic events among insulin- treated T2D, 
including severe hypoglycemia, is as high or higher than 
among those with T1D. Recent evidence suggests serious 
consequences of hypoglycemia may, in some respects, 
be greater in individuals with T2D, particularly regarding 
effects on the cardiovascular system. Hypoglycemia is 
generally patient- reported. Issues with hypoglycemia 
unawareness, limited glucose testing, limited recall, lack 
of event logging and fear of failure or shaming limits the 
number of hypoglycemic episodes reported by people 
with diabetes. Barriers to healthcare provider inquiry 
and reporting include lack of knowledge regarding 
the problem’s magnitude, competing priorities during 
patient visits, lack of incentives to report and limitations 
to documentation systems for adequate reporting. All 
people with diabetes should be encouraged to discuss 
their experiences with hypoglycemia without judgment 
or shame. Glucose targets, testing schedules (blood 
glucose or continuous glucose monitoring) and treatment 
plans should be reviewed often and individualized to the 
minimize risk of hypoglycemia. Finally, people with T2D on 
insulin should always be encouraged to have oral glucose 
and rescue medication immediately available.
INTRODUCTION
The risk of hypoglycemia in people with type 
1 diabetes (T1D) is clearly appreciated as a 
side effect of treatment. It is not as clearly 
understood in those with type 2 diabetes 
(T2D) treated with insulin. The risk of 
hypoglycemia in people with T2D has been 
considered less important, with the impli-
cation that it can often be ignored. Recent 
evidence contradicts this belief and suggests 
that serious consequences of hypoglycemia 
may, in some respects, be greater in indi-
viduals with T2D, particularly with regard 
to its effects on the cardiovascular system.1 2 
Furthermore, in older people with T2D who 
often live alone, comorbidities (eg, cognitive 
impairment and dementia, impaired renal 
function, other medications and frailty) can 
make hypoglycemia far more dangerous and 
difficult to manage.
Despite several studies addressing this 
topic,3–15 there are still lingering myths about 
hypoglycemia in people with T2D treated 
with insulin:
 Ź People with T2D rarely experience 
hypoglycemia.
 Ź People with T2D with elevated hemo-
globin A1c (HbA1c) are not at risk of 
hypoglycemia.
 Ź People with T2D can have hypoglycemia, 
but it is not severe due to the body’s 
counter- regulatory responses.
 Ź Hypoglycemia does not result in adverse 
consequences for people with T2D.
This narrative review aims to dispel these 
myths by examining the physiology, comor-
bidities and reported incidence and rates of 
hypoglycemia in people with T2D. Moreover, 
we consider why hypoglycemia is often under- 
reported and under- identified by individuals 
and healthcare providers (HCPs), and how we 
can improve hypoglycemia detection, preven-
tion and treatment education. Throughout 
this narrative review, the term ‘hypoglycemia’ 
is intended to generally refer to any level of 
severity; concepts related to ‘severe hypogly-
cemia’ are specified as such.
UNDERSTANDING HYPOGLYCEMIA FROM A 
MANAGEMENT PERSPECTIVE
Pathophysiology of hypoglycemia
In people without diabetes, hypoglycemia is 
rare since endogenous insulin secretion is 
inhibited as glucose levels fall below normal. 
Individuals with diabetes, treated with insulin, 
sulfonylureas or other insulin secretagogues, 
are at increased hypoglycemic risk because 
glucose levels will continue to fall until either 
insulin boluses or the effect of oral medication 
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are cleared. At diagnosis, individuals with diabetes are 
protected, at least in part, from the glucose- lowering 
effect of insulin by physiological responses initiated by 
stress pathways. As blood glucose falls below normal, 
glucagon is released by α cells probably due to a para-
crine response within the islets. Glucagon is a powerful 
counter- regulatory hormone that defends individuals 
against hypoglycemia by stimulating release of glucose 
from the liver through glycogenolysis.
With increased duration of diabetes, in both T1D 
and advanced T2D, progressive loss of β cells prevents 
paracrine cross- talk between the α and β cells leading to 
impaired glucagon release during hypoglycemia. This 
increases vulnerability to hypoglycemia. Thus, duration 
of T1D and, in T2D, the duration of insulin treatment are 
important predictors of hypoglycemic risk.
Those affected with declining β-cell function and 
impaired glucagon responses are still protected from 
hypoglycemia by activation of the sympathoadrenal 
nervous system and associated release of circulating 
epinephrine, but this defense also can become impaired. 
It is particularly sensitive to antecedent episodes of hypo-
glycemia, which reset the threshold for epinephrine 
release to a lower glucose level. One consequence is that 
the counter- regulatory response is delayed and, as glucose 
levels fall below 3 mmol/L (54 mg/dL), individuals can 
become cognitively impaired and are at major risk of a 
severe hypoglycemic episode. This has been described 
by some as ‘hypoglycemia- associated autonomic failure’. 
However, it is important to note that this condition is 
not closely related to diabetic autonomic neuropathy, 
which reflects structural and irreversible damage to the 
autonomic nervous system. Defective counter- regulatory 
responses to hypoglycemia as a result of antecedent 
episodes are functional rather than structural, at least in 
part. They can be reversed by scrupulous avoidance of 
hypoglycemia, an important treatment option in those 
affected in this way.
In summary, these pathophysiological changes, which 
both diminish symptomatic responses as well as reduce 
the ability of the body to resist the glucose- lowering 
effect of insulin, explain why individuals with T1D or 
long- standing T2D both are vulnerable to hypoglycemia 
during treatment.
Hypoglycemia prevalence in people with T2D
In a trial of participants with T2D treated with insulin 
glargine, hypoglycemia (defined as blood glucose 
≤3.3 mmol/L (60 mg/dL)) was detected in 56.9% of the 
participants by open- label, 3- day, blinded continuous 
glucose monitoring (CGM) as compared with 26.4% of 
the participants by their 8- point profile, self- monitored 
blood glucose.14 In a study using 5- day blinded CGM, 
Gehlaut et al found that 75% of participants with T2D were 
unaware of hypoglycemic episodes (defined as glucose 
<3.9 mmol/L (70 mg/dL)) detected by CGM.4 While best 
practice is to confirm suspected or CGM- identified hypo-
glycemia by self- monitored blood glucose, it is clear that 
much hypoglycemia objectively identified by CGM is not 
checked when CGM readings are not available in real- 
time. These studies suggest that the frequency of hypogly-
cemia in T2D is much higher than previously appreciated 
by both clinicians or people with T2D themselves.
Insulin treatment duration and hypoglycemia rates
In a multicenter observational study, UK researchers 
recruited individuals with either T2D or T1D to partici-
pate in a 9- month to 12- month prospective study in which 
their hypoglycemic burden was measured by question-
naires and CGM.16 People with T2D were divided into 
three treatment groups: insulin for <2 years, insulin for 
>5 years and sulfonylureas. The study reported in 2007 
that self- reported severe hypoglycemic episodes occurred 
in about 7% of the group with T2D who had been taking 
insulin for <2 years, a frequency comparable to the group 
taking sulfonylureas. The group with T2D taking insulin 
for over 5 years had a significantly higher risk of severe 
hypoglycemia, with around 25% reporting a severe hypo-
glycemic episode during the study. Thus, between 2 and 
5 years of insulin treatment, rates of self- reported severe 
hypoglycemia in individuals with T2D had tripled.
The UK Hypoglycaemia Study Group also reported 
that the proportion of patients with T2D taking insulin 
for over 5 years who reported at least one severe hypo-
glycemic event was comparable to that of adults with 
T1D diagnosed within the last 5 years, and lower than 
adults with T1D for >15 years.16 Although reported per- 
person- year rates of hypoglycemia are higher for T1D 
than insulin- treated T2D,5 there are many more people 
with insulin- treated T2D,17 18 resulting in more events of 
hypoglycemia (especially severe hypoglycemia resulting 
in hospitalization) among the insulin- treated T2D 
population.19
Consequences of hypoglycemia
It is beyond the scope of this review to give a detailed 
account of the consequences of hypoglycemic episodes, 
but recent trials have raised the possibility that, in addi-
tion to the well- recognized effects of hypoglycemia on 
the central nervous system, hypoglycemia may also have 
adverse consequences on the cardiovascular system.1 2 
Considerable evidence, including both clinical trials and 
observational studies, has demonstrated a consistent asso-
ciation between hypoglycemia and adverse cardiovascular 
outcomes. The current debate is focused on whether 
hypoglycemia is a risk factor, implying causality or merely 
a risk marker such that hypoglycemia is more common 
in vulnerable individuals due to frailty and comorbidity. 
In the absence of randomized controlled trials (RCTs), 
which are neither feasible nor ethical, it is challenging 
to prove this either way, although many believe that both 
mechanisms are contributing. However, the strength and 
consistency of the association reinforces the importance 
of choosing treatment which minimizes the risk of hypo-
glycemia, particularly in vulnerable individuals.
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Evidence also suggests a two- way relationship between 
hypoglycemia and impaired cognitive function and 
dementia. Significantly impaired cognition reduces the 
ability to self- manage diabetes, increasing the risk of 
hypoglycemia, while repeated hypoglycemia can lead to 
neurodegeneration, contributing to dementia and cogni-
tive decline.20 Non- severe hypoglycemia has also been 
found to decrease cognitive function during an insulin- 
induced episode in people with T2D.21
Hypoglycemia rates reported in clinical trials
The belief that hypoglycemia is less of a problem in T2D 
may stem, in part, from low rates reported for RCTs of 
individuals with newly diagnosed T2D. In the UK Prospec-
tive Diabetes Study (UKPDS), individuals with newly diag-
nosed T2D were assigned to either intensive treatment 
with insulin or a sulfonylurea, or conventional treatment. 
The UKPDS results published in 1998 showed that tighter 
glucose control reduced the incidence of microvascular 
complications, but increased the frequency of hypogly-
cemic episodes (0.7% per year with conventional treat-
ment vs 1.8% per year with insulin).22 For individuals who 
remained on the intensive treatment for 6 years, UKPDS 
researchers reported a frequency of 2.5% per year of what 
they described as ‘substantive hypoglycemic episodes’ and 
concluded that hypoglycemia was unlikely to be a barrier 
to achieving tight glucose targets using insulin or sulfony-
lureas.13 In the randomized controlled Diabetes Control 
and Complications Trial (DCCT) results published in 1997, 
benefits of intensive treatment were observed despite a 
marked increase in the rate of severe hypoglycemia.23
A newly diagnosed person with T2D is not representa-
tive of the typical insulin- taking person with T2D since, as 
described above, counter- regulatory defenses that confer 
protection against severe episodes are intact at diagnosis. 
At the time of the UKPDS and DCCT trials, it was perhaps 
underappreciated that conclusions based on a study in 
newly diagnosed individuals are, therefore, not a reliable 
guide to the risks of hypoglycemia in individuals with 
T2D on insulin. The need for insulin treatment in people 
with T2D reflects a progressive failure of β-cell secretion 
of endogenous insulin. Newly diagnosed individuals with 
T2D, if prescribed insulin, will require significantly less 
exogenous insulin and have a significantly better counter- 
regulatory response compared with individuals with 
advanced diabetes.24 However, insulin is not a first- line 
treatment recommendation for newly diagnosed individ-
uals with T2D25 and is not frequently prescribed in those 
individuals.24 26 On average, insulin was found to be initi-
ated in people with T2D >7 years after initiation of oral anti-
diabetic agent(s) even despite elevated HbA1c levels.26 The 
insulin resistance of T2D may also reduce hypoglycemic 
risk. As endogenous insulin diminishes, the physiological 
counter- regulatory defense also decreases, as described in 
Pathophysiology of hypoglycemia.24
Finally, prior to a recent International Hypoglycaemia 
Study Group position statement,27 no consistent, standard-
ized reporting of levels of hypoglycemia were used in clinical 
trials. Each clinical trial protocol defined the glucose levels 
used to determine hypoglycemic events, which contributed 
to the misconceptions about the prevalence and effects of 
hypoglycemia in people with T2D on insulin. The position 
statement provided guidelines for the standardization of 
reporting levels for hypoglycemia, with clinically important 
hypoglycemia (level 2) defined as glucose level <3 mmol/L 
(54 mg/dL) and severe hypoglycemia (level 3) denoted by 
severe cognitive impairment requiring external assistance 
for recovery.27 In addition, time- in- range goals have been 
defined as metrics for CGM.28
Clinical study design impacts hypoglycemia rate
We need to draw on studies that are population- based to 
provide an accurate measure of hypoglycemic risk in those 
with diabetes. A study by Donnelly et al published in 2005 
is one of the few that measured rates of hypoglycemia in a 
random sample of individuals with insulin- treated diabetes 
in a single city.3 This study measured rates of hypoglycemia 
over a 1- month period. They reported that participants 
with T2D treated with insulin had about 16 hypoglycemic 
events per person per year, with the equivalent of 0.35 
severe events per person per year. Significant predictors 
of hypoglycemia for people with T2D were a history of 
hypoglycemia and duration of insulin treatment. Other 
important risk factors include declining renal function, 
increasing age, impaired cognitive function and dementia.
More recent data from a global, multicenter study indi-
cate that the diabetes community may have underestimated 
the frequency of both severe and non- severe episodes of 
hypoglycemia. The Hypoglycemia Assessment Tool (HAT) 
study published in 2016 involved over 27 000 insulin- 
treated adults with T1D or T2D from 24 countries.5 Study 
centers were located in both high- income and low- income 
and middle- income countries and data were recorded both 
retrospectively and prospectively. In those with T2D, the 
overall rate of severe hypoglycemia was around 2.5 events 
per person per year, which is about seven times higher than 
the rate reported by Donnelly et al. In addition, there was no 
association between the rate of hypoglycemia and HbA1c 
in the HAT study, an observation also reported in other 
studies.8 29 It is likely that the method of recording, which 
involved online surveys, may have introduced a degree of 
selection bias; however, the high rates of hypoglycemia are 
of considerable concern despite these study limitations.
HYPOGLYCEMIA REPORTING
Patient under-identifying and under-reporting
As described above, hypoglycemia does occur in people 
with T2D; however, both recognition and reporting are 
limited. Effective mitigation measures can only be imple-
mented by the individual, the healthcare team and the 
payer once the incidence and causes of hypoglycemia are 
identified.
Although there are many potential sources of infor-
mation about the frequency and severity of hypogly-
cemic episodes in the general diabetes population, 
the individual is the primary source of information. 
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Unfortunately, people with diabetes often do not report 
hypoglycemic episodes to their HCPs. In one study, 67% 
of people with T1D and 43%–53% of those with T2D 
rarely reported hypoglycemia to their HCPs.12 In another 
study, 60% (T1D) and 46% (T2D) rarely or never report 
hypoglycemia to their HCPs.10 Given the central role 
of individuals in making HCPs aware of hypoglycemia, 
it is important to understand the process that gener-
ates opportunities for sharing and the factors affecting 
the responses to these opportunities. Below we describe 
this chain of events: (1) identifying/recognizing hypo-
glycemic events, (2) involving HCPs in treating hypogly-
cemic events, (3) recalling hypoglycemic episodes and 
(4) sharing information about hypoglycemic episodes 
during HCP visits.
Identifying/Recognizing hypoglycemic events
The first item in the chain is identifying/recognizing a hypo-
glycemic event. There is general understanding that individ-
uals with insulin- treated diabetes can develop impaired 
hypoglycemic awareness or hypoglycemic unawareness. 
This results in increased numbers of asymptomatic, 
non- severe hypoglycemic events,7 which contributes to 
a higher incidence of severe episodes when corrective 
action is not taken until hypoglycemic symptoms become 
severe.30 31 People with diabetes may not collect a glucose 
data point when experiencing hypoglycemia because 
they are occupied treating the low blood glucose. This 
limits any quantitative measure of the episode or a 
record for future analysis. Non- severe episodes can also 
be misinterpreted by people with diabetes and/or family 
members as a decrease in cognition, particularly in the 
elderly and not recognized as hypoglycemia. Moreover, 
one- third or more of people with T1D and T2D define/
identify hypoglycemia by the presence of symptoms.11 
Thus, only a portion of hypoglycemic episodes are avail-
able for sharing.
Involving healthcare providers in treating hypoglycemic events
The second item in the chain is involving HCPs in treating 
hypoglycemic events. HCPs often are not informed when 
hypoglycemia occurs, whether severe or non- severe; 
only 26% (T1D) and 33% (T2D) of people with diabetes 
sought medical care for hypoglycemic events and only 
24% (T1D) and 31% (T2D) consulted with their own 
physician/nurse.11 The opportunity for treatment 
support is missed, and sharing information with the indi-
vidual’s HCP requires a separate action following the 
event, which creates additional barriers to sharing.
Recalling hypoglycemic episodes
The third item in the chain is recalling hypoglycemic episodes. 
While almost 90% of individuals with a documented, 
severe hypoglycemic episode within the last year recalled 
that they had such an episode, those experiencing 
frequent episodes ‘had incomplete recall, resulting in a 
15% underestimation of the overall rate’.31 In a research 
study of mild hypoglycemia, recall was low over a 4- week 
period (48% for T1D and 75% for T2D)11; given the 
3- month to 4- month interval for routine diabetes care 
visits (even among conscientious individuals), it is likely 
that recall would be even lower during such visits.
Sharing information about hypoglycemic episodes during every 
healthcare provider visit
The fourth item in the chain is sharing information about 
hypoglycemic episodes during HCP visits. The loss of infor-
mation due to under- recognition and incomplete recall 
limits the information available for sharing. But even 
when individuals have the relevant information in hand, 
there are reasons they may not raise the subject of hypo-
glycemia. The needs of the individual and provider are 
not always aligned due to limitations in visit times and 
competing agendas. This can lead to less frequent inqui-
ries about hypoglycemia.
Beyond competing priorities, there may be specific 
disincentives in reporting hypoglycemic experience. For 
example, when EU legislation was implemented allowing 
withdrawal of a driver’s license for repeated, severe hypo-
glycemic episodes, the number of such episodes recorded 
in medical records during the year following enactment 
dropped by 55%.32 The conclusion that this was a result 
of reduced reporting rather than a reduced episode rate 
was supported by an anonymous survey of the cohort 
of 309 adults with T1D, which demonstrated that the 
medical record episodes were 70% lower than reported 
in the survey.32 Finally, HCPs sometimes express negative 
judgments to people with diabetes regarding less than 
desired treatment outcomes, which creates a barrier to 
sharing information about hypoglycemia. People with 
diabetes express hesitation to report episodes of hypo-
glycemia due to fear of HCP disappointment, as well as 
feelings of guilt and shame.33
Healthcare provider under-identifying and under-reporting
HCPs often under- identify and under- report episodes of 
hypoglycemia. The combination of HCP expectations/
beliefs regarding hypoglycemia, limited time during clin-
ical visits, variable degrees of provider- patient trust and 
competing agendas may all limit the HCP’s ability to 
identify or report hypoglycemia.
Expectations based on published rates of hypoglycemia
HCPs look to the literature for rates of hypoglycemia, but 
the available information can be confusing. For example, 
Elliot et al published a review of hypoglycemia rates 
from 19 RCTs and 11 real- world data studies.34 We might 
expect that the higher level of oversight, more frequent 
data collection, and increased expectations of individ-
uals enrolled in RCTs would increase the detection rate 
of hypoglycemia, but intensified patient follow- up and 
engagement decreases the actual incidence of hypogly-
cemia. Furthermore, individuals with an increased risk 
of hypoglycemia, including those with impaired aware-
ness, are frequently excluded from trials. Thus, rates of 
hypoglycemia are consistently higher in real- world data 
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studies compared with RCTs. This suggests that published 
rates of hypoglycemia from clinical trials underestimate 
the actual rate of hypoglycemia in the population, which 
may skew expectations of those who care for people with 
diabetes.
Patient history review
During routine visits, HCPs are often asked to record 
considerable clinical information and may be docu-
menting items such as date of the last eye examination 
or name of the podiatrist providing foot care. Patients 
report that their physicians frequently fail to inquire 
about hypoglycemia. In one study, 10% (T1D) and 13% 
(T2D) of people with diabetes reported that they were 
not asked about their hypoglycemia during consulta-
tions.10 Trying to cover all the required topics may be 
one reason that hypoglycemia is under- identified. This 
represents an HCP opportunity for increasing iden-
tification and reporting. Another lies with inquiry of 
the family or friends who accompany the person with 
diabetes. Asking for input from family members increases 
reporting of severe hypoglycemia and helps HCPs under-
stand the context and impact on the family and others.35
Hypoglycemia rates may not be reported to HCPs by 
people with diabetes because of the above- mentioned 
negative feedback. In office practices, the support staff 
may be the ones who inquire about hypoglycemia rates. 
One way to improve communication with the person with 
diabetes and the family is to normalize this question about 
hypoglycemia by asking every time and routinely using 
technology to capture glucose values. HCPs should at the 
very least inquire about low glucose values or awareness 
of hypoglycemia, but conversations regarding all aspects 
of diabetes care should be non- judgmental.
Quality measures and reporting tools
Consistent, clear documentation of frequency, timing 
and causes of hypoglycemia for people with T2D on 
insulin allows HCPs, health systems and payers to under-
stand the magnitude of hypoglycemia. Use of diabetes- 
out- of- control codes versus use of hypoglycemia codes 
buries the problem within the documentation systems. 
Standardization of reporting language in both trials and 
clinical settings is key to a clear understanding of the inci-
dence/prevalence and severity of hypoglycemic events.
The rate of hypoglycemia has not been a required field 
for ambulatory quality reporting measures in the USA, 
so providers and healthcare systems are not incentivized 
to document it. The focus for quality measures assessed 
by the National Committee for Quality Assurance has 
been on HbA1c testing and control, retinal eye exams, 
addressing nephropathy and blood pressure control.36
A workgroup convened by the American Diabetes 
Association and The Endocrine Society designed several 
tools to optimize collection of information around 
hypoglycemia and create a framework for addressing 
the problem.37 The workgroup created a one- page 
questionnaire for individuals and another checklist for 
providers to review at every visit.
HYPOGLYCEMIA DETECTION
Patient monitoring
Blood glucose monitoring
Home blood glucose monitoring is facilitated by easy- 
to- use portable devices. Some individuals with T2D test 
often, while some never test.38 The number and timing of 
prescribed glucose tests per day should be individualized 
to the needs of each person with diabetes.39 However, 
payers often restrict glucose monitor models and/or 
strip allowance and frequently change coverage yearly. 
Finally, out- of- pocket cost and the pain of the finger sticks 
also limit testing.
No consistency is found in the literature for the recom-
mended number of blood glucose tests per day for people 
with T2D on insulin. The American Diabetes Associa-
tion Standards of Care acknowledge the importance of 
blood glucose testing for those with T2D and recom-
mends an individualized approach to the frequency of 
testing.39 Rama Chandran et al found that four to five 
blood glucose tests per day was enough to predict hypo-
glycemia comparable to CGM.29 Although often resisted 
by people with diabetes, prediction and prevention of 
hypoglycemia is an excellent reason to suggest multiple 
daily blood glucose testing for people with T2D treated 
with insulin.29 40 A large observational study of patients 
in Italy found that 26.4% of participants tested blood 
glucose less than once a day and the incidence of hypo-
glycemia was inversely correlated with the number of 
daily blood glucose tests performed.41 In addition to 
scheduled blood glucose tests, blood glucose also should 
be tested when low glucose is suspected, either before or 
during treatment, and retested every 15 min after treat-
ment until resolution.39
In the clinical setting, people with diabetes are encour-
aged to bring their glucose monitors with them for 
data download. Some individuals bring their monitors, 
while others leave them at home. Some people with 
diabetes do not know how to interpret their glucose 
levels or how to improve their control.42 Digital data 
reports or paper logbook review at each visit allows for 
conversations between the person with diabetes and the 
healthcare team about glucose patterns (including hypo-
glycemic episodes), areas of success and areas of needed 
improvement.
If a person with diabetes receives limited to no feed-
back from the HCP about glucose levels, some will not 
consistently test. Inattention by the HCP to the glucose 
data reports can lead to lower individual motivation to 
test, record or report.43
Continuous glucose monitoring
CGM or flash glucose monitoring (FGM) may be 
preferred to blood glucose monitoring.9 44 Personal 
monitors provide glucose data to the person with diabetes 
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in real- time and all models have trending arrows that 
give insight into glucose trends. For many people with 
diabetes (whether T1D or T2D), asking them to perform 
a blood glucose fingerstick test multiple times per day can 
be an unrealistic expectation. The use of CGM or FGM 
provides multiple glucose measures throughout each 
24 hours period without frequent fingersticks. However, 
cost and coverage are limiting factors for widespread use 
in many countries.
Clinicians can intermittently use a one- time blinded 
CGM for a 6- day to 14- day data collection period 
(depending on the model) to assess glucose patterns.45–48 
As stated above, the use of CGM in research studies has 
demonstrated that people with T2D experience a higher 
than previously appreciated number of clinically relevant 
hypoglycemia episodes. Use of the CGM was shown to 
lead to treatment modification in 64.4% of CGM users 
(decreased drug dose, decreased drug frequency, change 
in drug administration timing, stopping drug completely 
or adjusting glucose targets).4
Tracking and logging
Electronic logbooks have entered the market and allow 
for more robust data capturing. Most blood glucose and 
CGM monitors allow the user and the HCP to connect 
to a mobile application or a professional data visualiza-
tion program to review and share data. However, not all 
the monitors and/or mobile applications track the level 
of detail required to fully understand the cause, severity 
of symptoms or treatments employed regarding a hypo-
glycemic episode. Until these meters or applications 
provide opportunity to capture these details, for some 
individuals, it may warrant keeping a paper log that is 
reviewed at each clinic visit. In elderly people, who are 
most at risk, relatives often need to be interviewed to 
provide the details of hypoglycemic episodes and causes 
and should attend visits whenever possible.
HYPOGLYCEMIA PREVENTION AND TREATMENT EDUCATION
Prevention
Prevention of hypoglycemia remains problematic as 
demonstrated by the high rates observed in various 
studies. The first step to prevention is acknowledgment of 
the risk of hypoglycemia in the T2D population treated 
with insulin. Next, avoidance of excess glucose fluctua-
tions should be an important consideration for reducing 
the risk of hypoglycemia in T2D. Consideration should 
be made for therapies that have a lower risk of glucose 
variability.29 The overall goal is not simply to lower the 
HbA1c, but to create stable glucoses in a range to decrease 
complications and reduce variability.6 49 50 When a CGM 
or FGM is used, review of the time graph and glucose 
profile with the patient allows for open discussions about 
incidence, timing and causes of hypoglycemia. Most 
importantly, ongoing review of the data accompanied by 
clear goals and an action plan should occur at every visit.
Treatment and prevention education
It is important to inquire about all levels of hypogly-
cemia at each visit with an open, shame- free discussion. 
The HCP and patient should collaborate to troubleshoot 
causes and create solutions.37 The Hypoglycemia Work 
Group provides a Hypoglycemia Patient Questionnaire 
and a Hypoglycemia Provider Checklist to guide these 
discussions.37 The International Hypoglycaemia Study 
Group has several resources available to support people 
with diabetes as well.51 We also advocate using patient 
portal communication to adjust therapies between visits 
as needed.
The frequency of severe hypoglycemia in T2D can be 
significantly reduced after participation in structured 
interventions that include patient education.52 We advo-
cate the training of providers (including primary care 
providers), staff, people with diabetes and their families on 
the creation of an action plan for timely and appropriate 
treatment of hypoglycemia. The International Hypogly-
caemia Study Group provides several resources to assist 
HCPs in the understanding of hypoglycemia causes and 
treatments.51 The use of oral glucose is preferred as first- 
line treatment when the person with diabetes is coherent 
and able to swallow. For anyone treated with insulin, a 
rescue treatment plan needs to be in place should the 
person with diabetes become unable to self- treat.39
CONCLUSION
Hypoglycemia has been found to contribute to cardio-
vascular and central nervous system harm in people 
with T2D. Hypoglycemia is a risk for people with T2D 
being treated with insulin, with reported rates of severe 
hypoglycemia around 2.5 events per person per year.5 
However, unless it is severe, hypoglycemia is primarily a 
patient- reported event and is not fully apparent in both 
recent trial design and in patient- provider interactions 
for people with T2D. An improved understanding of the 
barriers to accurate reporting would assist the diabetes 
community in estimating the frequency and severity of 
hypoglycemic episodes in people with T2D. Consistent 
clinical study designs that use standardized hypoglycemia 
reporting levels and definitions of time- in- range goals 
will contribute to the accurate assessment of hypogly-
cemic risk in people with T2D.
Barriers to the HCP, including competing priorities 
during patient visits, lack of incentives to report and limita-
tions to documentation systems, should be addressed 
to ensure hypoglycemia is assessed and recorded in all 
people with T2D on insulin. The collaboration between 
HCPs and people with T2D is a key component of 
hypoglycemia prevention, monitoring and treatment. 
Addressing issues surrounding hypoglycemia awareness, 
glucose testing, episode recall and event logging can 
improve reporting by people with diabetes. HCP feed-
back helps motivate people with diabetes to test, record 
and report glucose levels. All people with diabetes should 
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be encouraged to discuss their experiences with hypogly-
cemia without judgment or shame.
HCPs (including primary care providers), clinical staff, 
people with diabetes and their families should be encour-
aged to work together toward creating an action plan 
for timely and appropriate treatment of hypoglycemia. 
The ongoing review of glucose level data should occur 
at every clinic visit. Glucose targets, testing schedule and 
the treatment plan should be reviewed often and indi-
vidualized to minimize the risk of hypoglycemia. Finally, 
people with T2D on insulin should always be encouraged 
to have oral glucose and a rescue medication immedi-
ately available.
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